157 related articles for article (PubMed ID: 2443928)
1. Analysis of lymphokine-activated killer (LAK) cells.
Ortaldo JR
Prog Clin Biol Res; 1987; 244():197-206. PubMed ID: 2443928
[No Abstract] [Full Text] [Related]
2. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
5. Studies on lymphokine activated killer cells in the rat: analysis of precursor and effector cell phenotype and relationship to natural killer cells.
Hiserodt JC; Vujanovic NL; Reynolds CW; Herberman RB; Cramer DV
Prog Clin Biol Res; 1987; 244():137-46. PubMed ID: 2958869
[No Abstract] [Full Text] [Related]
6. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
Nishimura T; Burakoff SJ; Herrmann SH
J Immunol; 1989 Mar; 142(6):2155-61. PubMed ID: 2646377
[TBL] [Abstract][Full Text] [Related]
8. [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
He YD; Peng ZL; Liu SL; Wang H; Pan XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):810-2. PubMed ID: 17953364
[TBL] [Abstract][Full Text] [Related]
9. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
10. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
11. The effect of long-term cyclosporine therapy on natural killer cell activity.
Versluis DJ; Metselaar HJ; Bijma AM; Vaessen LM; Wenting GJ; Weimar W
Transplant Proc; 1988 Apr; 20(2 Suppl 2):179-85. PubMed ID: 3129839
[No Abstract] [Full Text] [Related]
12. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
Ting CC; Hargrove ME; Yun YS
J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells and tumor immunity: 1985.
Herberman RB
Year Immunol; 1986; 2():254-60. PubMed ID: 3033946
[No Abstract] [Full Text] [Related]
14. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
15. A mechanism by which human breast carcinoma cells escape the host immune system.
Hakim AA
Neoplasma; 1988; 35(6):691-705. PubMed ID: 3265486
[TBL] [Abstract][Full Text] [Related]
16. In vivo generation, enhancement and recruitment of host cellular immune responses against tumor: influence of MHC antigen expression on clones of tumor cell variants.
Fernández-Cruz E; Pérez M; Zabay JM; Garrido F
Prog Clin Biol Res; 1987; 244():115-25. PubMed ID: 2958867
[No Abstract] [Full Text] [Related]
17. [Fundamental and clinical aspects of adoptive immunotherapy with tumor-infiltrating lymphocytes].
Yahata G; Okada Y; Honda S; Tanaka K; Tokunaga A; Takahashi T; Seidou T; Takeuchi S
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1474-82. PubMed ID: 2471459
[TBL] [Abstract][Full Text] [Related]
18. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
Blanchard DK; Serbousek D; Djeu JY
Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
[TBL] [Abstract][Full Text] [Related]
19. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
20. Natural killer and other effector cells.
Stutman O; Lattime EC
Symp Fundam Cancer Res; 1986; 38():221-58. PubMed ID: 3489260
[No Abstract] [Full Text] [Related]
[Next] [New Search]